Investor Presentaiton
Commercial launch plans - US
Commercial ramp up during Q1 2022
Positioned to capture meaningful market share
•
Access to ~90% of eligible PET sites
Distribution network holds 60% market share of nuclear medicine
market in the US
On-demand pharmacy-based production with a
high yield product
Customer and patient scheduling flexibility
Market access strategy in place, commercial launch underway
•
•
Q1 focus on early adopters - imaging centers and veteran affairs
400 imaging centres pre-qualified
Telix + partners will have one of the largest commercial teams
(including sales, market access, MSL) to service the US prostate
imaging market
On track for reimbursement in H1 2022
•
HCPCS code expected 1 April 2022
Transitional Pass-Through (TPT)² status expected 1 July 2022
Telix partner sites
Current competitor sites
(19 January 2022)
For personal use only
1. Healthcare Common Procedure Coding System
Telix Pharmaceuticals Limited (ASX: TLX)
TELIX
PHARMACEUTICALS
Accessible
POWERED BY
68
Ga
Flexible
PSMA- Scarile Vial
Csere: 25 g of PSMA
(7C 8°C
for direct bu
NGUN
MOCKUP
Sterile Vacuumed Va
2°C
Frutus Refi
Patient-centered
Acetate Buffer
of Ac
N
24
24View entire presentation